Geocann expands cannabis scientific research leadership with first human β-caryophyllene (BCP) published study demonstrating the safety and performance of novel formulation FORT COLLINS, Colo., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Geocann is proud to announce that the peer-reviewed journal, Molecules, has published the results of a randomized, double-blind, cross-over...

Geocann and Pathway Health form a strategic partnership to supply VESIsorb® formulated medical cannabis products to leading retail pharmacy brands throughout Canada FORT COLLINS, Colo., Jan. 27, 2021 (GLOBE NEWSWIRE) -- Geocann is proud to announce a strategic partnership with Pathway Health Corp. (“PHC”) that will bring VESIsorb® formulated products to the...

Geocann reinforces its commitment to pioneering new clinical studies with the addition of internationally recognized medical researcher FORT COLLINS, Colo., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Geocann is proud to announce that Michael Davidson, M.D., has joined the company’s executive management team as Head of Innovation, Technology,...